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Abstract
Introduction: To address the need for remote assessments of cognitive decline and
dementia, we developed and administered electronic versions of the Clinical Dementia
Rating (CDR®) and the Financial Capacity Instrument-Short Form (FCI-SF) (F-CAP® ),
called the eCDR and eFCI, respectively.

Rachel L. Nosheny, Scott Mackin, and Michael
W. Weiner should be considered joint senior
authors.

Methods: The CDR and FCI-SF were adapted for remote, unsupervised, online use
based on item response analysis of the standard instruments. Participants completed
the eCDR and eFCI first in clinic, and then at home within 2 weeks.

Funding information
The National Institute on Aging of the National
Institutes of Health, Grant/Award Number:
RF1AG059909

Results: Of the 243 enrolled participants, 179 (73%) cognitively unimpaired (CU),
50 (21%) with mild cognitive impairment (MCI) or dementia, and 14 (6%) with an
unknown diagnosis, 84% and 85% of them successfully completed the eCDR and eFCI,
respectively, at home.
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Discussion: These results show initial feasibility in developing and administering
online instruments to remotely assess and monitor cognitive decline along the CU to
MCI/very mild dementia continuum. Validation is an important next step.
KEYWORDS

aging research, Alzheimer’s disease, Brain Health Registry, internet, remote online instruments

1

INTRODUCTION

the Brain Health Registry (BHR) internet-based platform.17,18 The
eCDR and eFCI, if validated, have the potential to facilitate clinical AD

The development of psychometrically validated assessments to iden-

research and health care, by allowing remote assessment of cognition

tify older adults at risk for cognitive decline and dementia due to

and function in an inexpensive, efficient, and scalable way.

Alzheimer’s disease (AD) is a critical need for clinical researchers.
However, many assessments for clinical research, treatment trials, and
clinical practice are conducted in person at a research clinic, which can

2

METHODS

be time consuming and expensive.1,2 In addition to the increase in older
adults using the internet for a wide variety of activities,3,4 internetbased patient communication, including cognitive assessments, is

2.1
Description of the traditional instruments:
CDR and FCI-SF

increasing in health-care settings. There are currently over 40 different
computerized neuropsychological tests, although most have not been

2.1.1

Clinical Dementia Rating (CDR)

clinically validated for unsupervised, at-home use.4–7 The COVID-19
pandemic underscores a pressing need for the development and vali-

The CDR, developed at Washington University in St. Louis (WU), is

dation of inexpensive, scalable online methods to remotely assess and

used to detect the presence of dementia and when present, to deter-

longitudinally monitor individuals, which may help to facilitate AD clin-

mine the extent of cognitive and functional decline.9,10 Using their

ical trials and accelerate the development of new treatments more

best judgment, a clinician obtains the information necessary to assign a

efficiently.

CDR score by conducting semi-structured interviews with a participant

Measures of cognition and activities of daily living have been

and their study partner (typically, a spouse or adult child). Impairment

demonstrated to be highly valuable for clinical AD research, especially

is scored based on decline from a previously obtained level of func-

for detecting early changes that predict future decline and disease

tion and is rated in six categories: Memory, Orientation, Judgment and

progression.8 One well-validated measure of cognitive and functional

Problem Solving, Community Affairs, Home and Hobbies, and Personal

decline is the Clinical Dementia Rating

(CDR®),9–11

which is widely

Care. Each category is rated independently across five levels of impair-

used to characterize progression of AD and related dementias. Semi-

ment: none (0), very mild (0.5), mild (1), moderate (2), and severe (3);

structured interviews with a participant and a study partner are used

an exception is the Personal Care domain, which is rated as 0, 1, 2, or

to calculate cognitive and functional status scores across six domains,

3. Scores in each category are synthesized to yield a global CDR score

as well as a composite or global CDR score. Another well-validated

on an ordinal 5-point scale, on which CDR 0 indicates normal cognition

measure is the Financial Capacity Instrument-Short Form (FCI-SF) (F-

and CDR 0.5, 1, 2, and 3 designate very mild, mild, moderate, and severe

CAP® ),12–16 which is used to detect decline in everyday financial skills

dementia, respectively.

in older adults. The FCI-SF is a performance-based assessment of four

Attributes of the CDR include multidimensional assessment of

financial domains including monetary calculation skills, financial con-

cognition, behavior, and function and linkage to validated diagnostic

ceptual knowledge, understanding/using a checkbook and register, and

criteria for dementia due to AD.19,20 The CDR is scored independently

understanding/using a bank statement. Items are scored and summed

of neuropsychological test (NPT) performance, so NPT data can remain

to calculate four component performance scores and a total score in

as independent variables in longitudinal studies. Because the instru-

addition to timing indexes of four tasks.

ment assesses decline from a person’s previous level of function, it also

Although both the CDR and FCI-SF are well validated in clinical

lessens the influence of age,21 education, linguistic, and sociocultural

settings, there are limitations that hinder their accessibility and scal-

confounders.22 The CDR has high inter-rater reliability in multi-center

ability. Both require administration in a supervised setting with an

trials,10,23–25 strong content and criterion validity,26 and internal con-

experienced and certified rater, and therefore have high burden for

sistency and internal responsiveness.27 There are well established,

administrators2

We developed online versions of

standard training and certification protocols10 to stably administer the

both instruments, called the electronic CDR (eCDR) and the electronic

CDR and assess cognitive impairment.28 Because the CDR captures

Financial Capacity Instrument-Short Form (eFCI) and assessed the fea-

clinically meaningful change,29 it has been proposed as the primary

sibility of implementing these newly developed instruments through

outcome measure in many AD clinical trials.

and

participants.1
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RESEARCH IN CONTEXT
1. Systematic Review: A PubMed search was conducted to
review: (1) currently available computerized neuropsychological tests and remotely administered cognitive and
functional assessments in older adults; (2) internet and
technology use by older adults; (3) evidence for use of
cognitive and functional measures in AD research; and
(4) content, psychometric properties, and validity of the
Clinical Dementia Rating (CDR) and Financial Capacity
Instrument-Short Form (FCI-SF).
2. Interpretation: Our findings demonstrate the feasibility
of implementing the electronic versions of the CDR and
FCI (eCDR and eFCI) in a cohort of older adults with unimpaired cognition, mild cognitive impairment (MCI), and
very mild dementia.
3. Future Directions: Ongoing analyses are now validating
the eCDR and eFCI by: (1) comparing performance on
e-instruments to their in-clinic counterparts, (2) estimating associations between e-instrument performance and
in-clinic neuropsychological tests, and (3) assessing the
sensitivity and specificity of the e-instruments to detect
MCI. Future studies will validate the instruments in more
diverse populations.

2.2
Statistical analysis of existing data: CDR and
FCI-SF
To inform item selection for the electronic versions of the CDR and FCISF, item response theory (IRT)30 analysis of existing CDR and FCI-SF
clinical data was performed for this study. The IRT analysis approach
was used to identify specific items that were most informative in
estimating the underlying degree of cognitive/functional impairment;
these items were kept in the electronic instrument. IRT analysis was
also used to identify specific items that had less sensitivity, poor psychometric properties, and that contributed the least information in
estimating the underlying degree of cognitive/functional impairment;
these items were eliminated from the electronic instrument. Ordinary least squares linear regression analysis also was used to measure
associations between individual items and overall instrument score.
IRT analysis for the CDR included item-level data from WU’s Memory and Aging Project.31 The WU dataset contained >3000 records
with 65 items measuring the six subdomains of the CDR. IRT analysis
of the CDR indicated that the majority of the items in the CDR discriminated well at mild and very mild levels of cognitive impairment.32
Of the original 65 items, 53 informative items that had demonstrated
high discriminative power were kept in the final statistical model for
estimation of overall and domain specific scores.31,32
IRT analysis for the FCI-SF used item-level data from the Mayo
Clinic Study of Aging (n = 1472)33 and the Cognitive Observations in
Seniors (COINS) study at UAB (n = 144).34 Statistical IRT and differential item functioning (DIF) analysis of the FCI-SF indicated that the
majority of the items in the FCI-SF discriminated well between individuals with varying levels of financial capacity and required either a

2.1.2

Financial Capacity Instrument (FCI-SF)

higher or lower level of financial capacity to be answered correctly.35
All FCI-SF items, including interrelated tasks, were retained in the

The FCI-SF, developed at the University of Alabama at Birmingham

eFCI.

(UAB), is a 15-minute measure that uses performance and time-tocompletion variables to detect decline in everyday financial cognition
in older adults.14 The measure uses financial concepts, coins/currency,

2.3

Development of electronic instruments

documents, and other financially related stimuli relevant to the monetary system and financial practice of the US population. The FCI-SF,
derived from the FCI-Long Form (FCI-LF), comprises 37 performance

2.3.1
Overall approach to adapt traditional
instruments into online instruments

items that evaluate four financial domains: monetary calculation, conceptual knowledge, using a checkbook/register, and using a bank

To adapt the CDR and the FCI-SF for online administration, each item

statement.13 The FCI-SF also includes six processing speed indexes,

was reviewed to first determine whether it could be reasonably trans-

measuring the time-to-completion of four specific FCI tasks. Total

lated into an online format. The overall approaches used to adapt the

performance scores range from 0 to 74 points and the six time-to-

CDR and the FCI-SF for online use are described in Table 1. Items with

completion indices include a maximum composite time of 670 seconds.

discrete response options (e.g., yes/no) were adapted verbatim in a sim-

The FCI-SF also includes four unscored yes/no questions concerning

ple survey format (Table 1, Row 1). Items with open-ended responses

a participant’s prior experience with specific financial tasks. The FCI-

were altered to have multiple-choice options (Table 1, Row 2) or drop-

SF requires a trained rater and has a detailed and well-operationalized

down menus. To preserve the integrity of online data collection for

administration and scoring manual. Age- and education-adjusted older

these instruments, multiple choice and drop-down menu options were

adult norms for the FCI-SF have been published.12 The FCI-SF has been

generated that contained a list of the most frequent responses. Inves-

associated with dementia progression and has shown sensitivity to

tigators used their extensive experience with the CDR and the FCI-SF

amyloid beta (Aβ) status in cognitively unimpaired (CU) older adults.14

to identify and develop a list of the most frequent responses to open-

The FCI-SF has also been shown to have excellent internal reliability,

ended questions. For items likely to show practice effects, such as the

interrater reliability, and concurrent validity with the FCI-LF.12

short memory test within the CDR and the items requiring specific
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Approaches used to adapt traditional CDR and FCI-SF online use
Type of response/test
materials

Adaptation

CDR

Discrete response
options (e.g., yes/no)

Simple survey format

CDR

Open-ended response
field for written text

Multiple choice answer
options or dropdown
menus

FCI-SF

Open-ended response
field for written text

Multiple choice answer
options

CDR

Open-ended response
field for numerical
response

“Slider” question type for
numerical questions

CDR

Verbal reminders with
extra details frequently
provided by assessors
during in-clinic
assessments

Extra details were
included as
supplemental text

Example figure(s)

(Continues)
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TA B L E 1

Test

(Continued)
Type of response/test
materials

Adaptation

Example figure(s)

FCI-SF

Physical stimuli provided
to participant
(examples: check book,
blank checks and check
register)

Images of physical stimuli
were displayed on
device screen

FCI-SF

Physical stimuli provided
to participant to make
out a check

Images of a check with
clearly highlighted
fields to identify
different parts of the
check that were
specific to the question
being asked

FCI-SF

Verbal instructions to
have scratch paper, a
pencil, and a calculator
readily available

Written instructions
were displayed on
device screen

FCI-SF

Verbal reminders follow
along with the
administrator as they
read the question
aloud

Written reminders to
scroll down to read and
answer the question
were displayed on
device screen

Abbreviations: CDR, Clinical Dementia Rating; eCDR, electronic Clinical Dementia Rating; eFCI, electronic Financial Capacity Instrument; FCI-SF, Financial
Capacity Instrument – Short Form.

calculations in the FCI-SF, alternative versions of items were devel-

Some items, such as the autobiographical recall question,36 in the

oped. All potential items were evaluated by the study team, including

CDR that could not be reasonably translated into an online format

clinicians familiar with the in-clinic administration of the instruments,

due to their open-ended nature (10% of CDR questions) were elimi-

to determine item content and wording, as well as the importance of

nated from the eCDR (Table 2) or were altered to have a wide range

clinical judgment. The instruments were adapted for online use via

of answer options. For example, the “slider” Qualtrics response type

Qualtrics software (https://www.qualtrics.com), a survey software tool

was used for numerical questions (Table 1, Row 4). Another challenge

for data collection. The eCDR can be administered on smartphones,

was administering and scoring the adapted eCDR without the ability to

tablets, and computers, whereas the eFCI is optimally administered on

ask follow-up questions and without the judgment of an experienced

tablets or computers due to screen size requirements for the tasks.

assessor. To address this, extra details that assessors most frequently
provided during past in-clinic assessments were included as supplemental text in the eCDR. For example, because the CDR was intended

2.3.2

eCDR development

to assess decline from a person’s previous level of function, reminders
for the study partner were incorporated throughout the eCDR to only

The eCDR was developed collaboratively between the University of

endorse an answer if the participant’s observed behavior was: consis-

California San Francisco (UCSF) and WU. Additional methods were

tent, a change compared to the participant’s longstanding behavior,

used to address challenges specific to adapting the CDR instrument.

due to memory and thinking problems, and interfered with the partic-
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TA B L E 2
eCDR

Items eliminated from the CDR to adapt for online use in

adapting the FCI-SF for online use. An alternative version of the FCISF was created for development of the eFCI: 100% of the alternative

Type

Question

SP

Is he/she taken to social functions outside a family home? If no,
why not?

FCI-SF items were adaptable for online use. The eFCI captured timing
information for each item and was expected to take a total of 20 minutes to complete. Similar to the issue for the CDR, the FCI-SF required a

SP

If in nursing home, does he/she participate well in social
functions (thinking)?

trained rater to administer the FCI-SF in clinic. To address this, we used

SP

If in nursing home, what can he/she no longer do well (H and
H)?

frequent responses and intentional foil responses, as well as additional

SP

Ability to perform household tasks: Please describe (Blessed)

that could be scored automatically without a rater. We also included

SP

Tell me about some recent event in his/her life within 1 week
(autobiographical)

instructions for participants at the beginning and throughout the eFCI

Tell me about some recent event in his/her life within 1 month
(autobiographical)

use (Table 1, Row 8). Another challenge was adapting the physical stim-

SP

multiple-choice answers or drop-down menus that contained the most
text within the electronic instrument instructions, to create an eFCI

to have scratch paper, a pencil, and a calculator readily available for
uli, such as a checkbook and bank statement, used in the FCI-SF. We

P

A few moments ago within 1 week (autobiographical)

created images of the physical stimuli used in clinic that display on

P

A few moments ago within 1 month (autobiographical)

the participant’s device screen, including a bank statement, checkbook,

P

What is the name of this place?

check register, and a blank check with clearly highlighted fields to iden-

P

Upon arriving in a strange city, how would you locate a friend
you wanted to see?

Abbreviations: CDR, Clinical Dementia Rating; eCDR, electronic Clinical
Dementia Rating; P, participant; SP, study partner.

ipant’s daily function (Table 1, Row 5). A related challenge in adapting
the CDR for online use was replicating the clinician’s judgement used

tify different parts of the check specific to the question being asked
(Table 1, Row 7). An automatic eFCI scoring algorithm was developed.
Pilot data and user feedback from internal alpha testing were used to
make minor changes to optimize the eFCI.

2.4
Feasibility of implementing electronic
instruments

to assign a CDR score based on a participant’s or study partner’s
responses. To address this, a standard, automated scoring algorithm

2.4.1

Participants

was developed based on the IRT model to remotely score the eCDR
without clinician judgment.31,32 Li et al.32 described further details

Participants and study partners were recruited into the Electronic Val-

on the IRT analysis and the development of the automated scoring

idation of Online Methods to Predict and Monitor Cognitive Decline

algorithm for the eCDR. The algorithm generates multiple outcome

(eVAL) study from two sources. First, we referred current BHR par-

measures: categorical global and box scores (like the CDR), and novel,

ticipants to the study using automated e-mail invitations17 with the

continuous global and box scores. The eCDR scoring algorithm has

following inclusion criteria: agreed to be contacted about future

more granular scoring than the CDR, giving it the potential for higher

studies, 55 years of age and older, residing within 50 miles of the

sensitivity to identify subtle cognitive and functional changes in largely

UCSF site.17 Second, participants were recruited from existing clini-

CU individuals with a CDR = 0. Last, the CDR relies heavily on the

cal cohorts from three Alzheimer’s Disease Research Center (ADRC)

accuracy of study partner responses, and the accuracy of study part-

sites: UAB, Mayo Clinic (Mayo), and WU. All participants signed con-

ner responses is judged by the assessor based on the dyad relationship.

sent during their in-clinic visit, and all activities were performed under

To address this, the eCDR asks both the participant and the study part-

institutional review board approval at the local site.

ner questions such as how long they have known each other, whether
they currently live together, and how many hours per week they spend
together. The participant portion of the eCDR was expected to take

2.4.2

Electronic instrument implementation

a total of 15 minutes, and the study partner portion of the eCDR
was expected to take a total of 20 minutes. Pilot data and user feed-

In-clinic visits occurred annually during which a trained study staff

back from internal alpha testing were used to make minor changes to

member administered the CDR, FCI-SF, eCDR, and eFCI in a supervised

optimize the eCDR.

testing session. Participants were assisted at the beginning of the electronic instrument (e-instrument) and had the option to get help from
the study staff member as needed. Within 2 weeks of the supervised

2.3.3

eFCI development

visit, participants returned home, completed registration on the BHR
platform by following instructions provided in the invitation e-mail and

The eFCI was developed in collaboration between UCSF and UAB and

completed the eCDR and eFCI in an unsupervised setting at home with-

in consultation with co-author Dr. Marson, the creator of the FCI-SF.

out a study staff member. The supervised in-clinic e-instrument version

Additional methods were used to address the challenges specific to

was taken before the unsupervised at-home e-instrument version in all
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cases, which may represent a confound. This is a limitation that will be
addressed in the Discussion section.
The eCDR and eFCI included instructions emphasizing that the
participant should complete the instrument “entirely on his/her own,
without any assistance.” After the baseline in-clinic visit, participants
were asked to complete the eCDR and eFCI every 6 months at home
in an unsupervised setting. Study partners were also asked to complete the eCDR in an unsupervised setting through the BHR platform

TA B L E 3

Completion of electronic instruments

Variable

UCSF

ADRC

Total

Invited

2915

277

3192

Enrolled

140 (5%)

103 (37%)

243 (8%)

Completed P eCDR
in-clinic

136 (97%)

100 (36%)

236 (74%)

Completed P eCDR at
home

135 (96%)

72 (70%)

207 (85%)

Completed SP eCDR
at home

124 (89%)

68 (66%)

192 (79%)

Completed eFCI
in-clinic

136 (97%)

101 (98%)

237 (98%)

Completed eFCI
at-home

134 (96%)

71 (69%)

205 (84%)

on the same timeline. Using the BHR platform, participants and study
partners registered by creating a username and password, agreed to
an online informed consent, and completed the electronic instruments.
Participants were also asked to self-report “How confident are you
with computers?”, with the option to endorse “Not confident at all,”
“I usually need help,” “It depends on the task,” or “Confident.” Automatic e-mails were sent to participants and study partners on 1, 3, 5,
11, and 15 days after their at-home visit due date and phone calls were
made to participants and study partners on approximately 8 and 18
days after their at-home visit due date to remind them of their at-home
and in-clinic visits and study tasks.

2.4.3

Notes: Enrolled percentages indicate number enrolled out of invited participants; completed percentages indicate number that completed task out of
number enrolled. Data presented as number as of January 5, 2022.
Abbreviations: ADRC, Alzheimer’s Disease Research Center; eCDR, electronic Clinical Dementia Rating; eFCI, electronic Financial Capacity Instrument; P, participant; SP, study partner; UCSF, University of California San
Francisco.

Clinical diagnoses

The Uniform Data Set, Version 3 (UDS)37 was administered to all par-

are shown in Table 3. Out of all 3192 participants invited to enroll in the

ticipants. Clinical diagnosis of CU, mild cognitive impairment (MCI), or

study, 250 (176 invited from BHR and 74 invited from ADRCs) declined

mild dementia were obtained from the UDS section D1.

consent or withdrew from the study. Most common specified reasons
for declining consent or withdrawing from the study are included in
Table 4. Seventy-seven participants were determined ineligible and

2.5

Statistical analysis

excluded.

To assess the reliability between the unsupervised at-home eCDR and
the supervised in-clinic eCDR, McNemar’s Chi-square test was per-

3.2

Characteristics of enrolled participants

formed on a 2 × 2 table of at-home and in-clinic eCDR results of 0 or 0.5
(n = 189). Because one of the cell counts was small (<5), continuity cor-

Table 5 summarizes the demographic profile, clinical diagnoses, and

rection was applied. We also calculated the mean and median total time

computer confidence of participants. Of all enrolled participants, 179

it took both participants and study partners to complete their portion

(73%) were CU, 49 (20%) had MCI, 1 (1%) had dementia, and 14 (6%)

of the eCDR (n = 207 pairs). For the eCDR, we removed outliers based

had an unknown diagnosis.

on the 1.5× interquartile range (IQR) rule. This was necessary because
the initial total time included the sum of any pauses and re-starts taken
resulting in highly right-skewed values.
A Pearson correlation coefficient was calculated to assess the reli-

3.3
Reliability between in-clinic and at-home
administration and completion times

ability between the unsupervised at-home eFCI and the supervised
in-clinic eFCI (n = 209). We also calculated the mean total time to

The reliability between the supervised in-clinic eCDR and unsuper-

complete the eFCI (n = 209).

vised at-home eCDR was estimated with a McNemar’s Chi-squared
test statistic of 0.364 with degrees of freedom equal to one and associated P-value of .547 (with continuity correction). This supports high

3

RESULTS

test–retest reliability of the administration setting of the eCDR, meaning there is not a significant difference between eCDR scores taken

3.1
Feasibility of electronic instrument
implementation

in clinic from those taken at home. The mean total time to complete
the participant portion of the eCDR was 12 minutes and 24 seconds
(median: 12 minutes and 20 seconds). The mean total time to complete

Between January 17, 2020 and January 5, 2022, there were 243 par-

the study partner portion of the eCDR was 16 minutes and 28 seconds

ticipants enrolled across all sites. Enrollment and task completion rates

(median: 16 minutes and 3 seconds).
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TA B L E 4

Summary of declined reasons and exclusion reasons

Declined or exclusion reason

Total

Reason for declining consent

250a

Participant does not specify reason

TA B L E 5

Characteristics of participants

120 (48%)

Enrolled at
UCSF
N = 140

Enrolled at
ADRCs
N = 103

Total
enrolled at
all sites
N = 243

73 (67–79)

74 (67–78)

74 (67–79)

82 (59%)

43 (42%)

125 (51%)

Overall not interested

70 (28%)

Too much time

18 (7%)

Age years, median (IQR)

Inability to use a computer

16 (6%)

Female (%)

Unable to come into clinic

13 (5%)

Education

No available study partner

11 (4%)

High school

2 (1%)

8 (8%)

10 (4%)

Study partner doesn’t want the participant to be
involved

10 (4%)

Some college

8 (6%)

9 (9%)

17 (7%)

Medical reason

9 (4%)

COVID-19 related concerns

7 (3%)

Not a good time for participant

7 (3%)

Not willing to complete assessments

3 (1%)

Involved in other studies

3 (1%)

Death

2 (1%)

Lack of access to a computer or internet at home

1 (0.4%)

Reason for exclusion

77a

Demographics

Two-year degree

5 (4%)

5 (5%)

10 (4%)

Four-year degree

40 (29%)

31 (30%)

71 (29%)

Master’s degree

55 (39%)

30 (29%)

85 (35%)

Doctoral degree
Professional degree
Unknown

12 (8%)

2 (2%)

14 (6%)

18 (13%)

6 (6%)

24 (10%)

0 (0%)

12 (11%)

12 (5%)

115 (82%)

90 (87%)

205 (84%)

1 (1%)

11 (11%)

12 (5%)

Race
White (%)

No available study partner

22 (29%)

Black or African
American (%)

Inability to complete computer tasks at home

17 (22%)

Asian (%)

13 (9%)

0 (0%)

13 (5%)

Medical reason

10 (13%)

More than one race (%)

10 (7%)

0 (0%)

10 (4%)

Does not specify reason

10 (13%)

American Indian or
Alaskan Native (%)

0 (0%)

0 (0%)

0 (0%)

Native Hawaiian or Other
Pacific Islander (%)

0 (0%)

0 (0%)

0 (0%)

Unable to come into clinic

7 (9%)

Participates in other research activities

5 (7%)

Study partner doesn’t want the participant to be
involved

4 (5%)

Decline to State (%)

1 (1%)

1 (1%)

2 (1%)

Unknown (%)

0 (0%)

1 (1%)

1 (1%)

8 (6%)

0 (0%)

8 (3%)

132 (94%)

98 (95%)

230 (95%)

Declined to state (%)

0 (0%)

3 (3%)

3 (1%)

Unknown (%)

0 (0%)

2 (2%)

2 (1%)

110 (79%)

69 (67%)

179 (73%)

30 (21%)

19 (18%)

49 (20%)

Dementia (%)

0 (0%)

1 (1%)

1 (1%)

Unknown (%)

0 (0%)

14 (14%)

14 (6%)

1 (1%)

2 (2%)

3 (1%)

Depends on task (%)

42 (30%)

30 (29%)

72 (30%)

Confident (%)

94 (67%)

45 (44%)

139 (57%)

Unknown (%)

3 (2%)

26 (25%)

29 (12%)

Lost to follow up

1 (1%)

COVID-19 related concern

1 (1%)

Participant not able to complete assessments

1 (1%)

Hispanic or Latino (%)

Study Partner doesn’t speak English

1 (1%)

Not Hispanic or Latino (%)

Note: Data presented as number (%) as of January 5, 2022.
a
Unique count of participants as more than one reason can be endorsed.

Ethnicity

Diagnosis
Cognitively unimpaired (%)

The Pearson correlation coefficient between the supervised inclinic eFCI and the unsupervised at-home eFCI was 0.731 (P < .001).
This supports a high correlation between the eFCI completed in clinic
and at home. The mean total time to complete the eFCI was 13 minutes
and 38 seconds (±4 minutes and 39 seconds).

Mild cognitive
impairment (%)

Computer confidence
Usually needs help (%)

4

DISCUSSION

The development of online unsupervised cognitive assessments can
improve the accessibility of existing instruments used to identify, diagnose, and monitor individuals at risk for cognitive decline. We adapted
the traditional in-clinic CDR and FCI-SF by developing the online
unsupervised eCDR and eFCI instruments and automated scoring algorithms for each instrument. Our preliminary results demonstrated

Abbreviations: ADRC, Alzheimer’s Disease Research Center; IQR,
interquartile range; UCSF, University of California San Francisco.
Note: Data presented as median (IQR) or number (%) as of January 5,
2022.
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feasibility (the ability of a participant to complete all aspects of

the potential to expand accessibility to these valuable measures of

the electronic instrument) of our approach. We are now validating

cognitive and functional status, particularly for individuals who do

the e-instruments against traditional instrument counterparts, clin-

not have access to a research clinic due to where they live or other

ical diagnosis of CU or MCI/very mild dementia, and exploring the

logistical constraints that are known to unduly burden URPs.41–53 As

relationship between e-instrument performance and other important

digital technology and internet use among older adults, including URPs,

outcomes, such as clinical diagnosis and in-clinic neuropsychologi-

continues to grow, online assessment approaches show promise as a

cal test performance. If validated, these novel e-instruments would

feasible, valid approach.17,18,54–60 However, lack of access to technol-

help facilitate screening and assessment of older adults for AD clini-

ogy remains a concern for making these assessments available to those

cal trials, AD clinical research, and clinical care. Further, they can be

with lower socioeconomic status. Further, because 30% of participants

used for population-based screening for early detection of cognitive

expressed that their confidence using a computer “depends on the

impairment, and for epidemiological studies.

task,” it will be important to explore the contribution of computer con-

A significant component of e-instrument adaption was developing

fidence to e-instrument performance in future analyses. The current

an algorithm-based instrument that would not require a clinician to

sample includes 73% CU individuals and 20% with MCI. The current

score responses using clinical judgment. To do so, we included items

study focuses on the potential of the e-instruments to detect/screen

that were identified by clinicians as having significant influence on

for early stages of cognitive impairment. It will be important to address

clinician judgment and score assignment. In addition, to best mimic

whether the e-instruments are feasible and valid in a sample with a

in-clinic administration, we incorporated in the e-instruments specific

broader range of cognitive impairment in future studies, and to iden-

examples and content for answer choices, as well as extra details and

tify the level of cognitive impairment at which participants are unable

prompts that clinicians most frequently used such as instructions to

to reliably complete e-instruments.

have scratch paper, a pencil, and a calculator readily available and

Finally, in our study, we did not counterbalance the order of e-

reminders to scroll down to view the entire question in the eFCI

instrument administration (in clinic vs. at home), due to current clinical

(Table 1, Rows 8 and 9). Additionally, we used multiple-choice answers

protocols at the sites. Therefore, we could not address the degree to

rather than have open-ended response fields. However, presenting a

which the initial, supervised administration influenced the subsequent,

list of multiple-choice answers may have inherently prompted partic-

unsupervised e-instrument performance. Further, although we have

ipants, diminished the use of a participant’s abstract thinking to craft a

included clear instructions for participants to complete the eCDR and

response, and possibly changed the construct of the question. To recon-

eFCI without any assistance, it is possible that the study partner or

cile this in the development of the eCDR and the eFCI, multiple-choice

someone else may have helped the participant during unsupervised

options and dropdown menus were created to present and capture

visits.

a wide range of answer responses. Adaptations to existing scoring

The goal of this article is to describe the methods used to develop

algorithms were made to incorporate the addition of multiple-choice

the eCDR and eFCI, and to present evidence for feasibility of their

answers.

remote administration in a cohort of older adults. Ongoing analyses

We have implemented the eCDR and eFCI using the BHR platform

are now validating the eCDR and eFCI as novel measures to detect

and have collected data from participants across four clinical sites

and monitor cognitive and functional decline. Future analyses will: (1)

(UCSF, WU, UAB, and Mayo Clinic). This supports previous studies

compare performance on e-instruments to their in-clinic counterparts,

that have demonstrated the feasibility and benefit of leveraging unsu-

(2) estimate associations between e-instrument performance and both

pervised, online measures as a scalable approach to assess cognitive

baseline and longitudinal change in in-clinic neuropsychological tests

and functional decline and to improve the efficiency of screening and

from the UDS, and (3) assess the sensitivity and specificity of the

recruitment for clinical trials.38–40

e-instruments to detect MCI. We also plan to investigate the associa-

While our results demonstrate that development and implemen-

tion between e-instrument performance and AD biomarkers, including

tation of these new online measures is feasible, we acknowledge

amyloid and tau. If validated, the eCDR and eFCI will have many,

limitations in our study. First, we acknowledge selection biases that

high-impact applications in the Alzheimer’s disease and related demen-

may limit generalizability of our results. Our sample includes only

tias and public health fields. They can be used to efficiently screen

individuals who have access to the internet, are computer literate,

participants for preclinical and prodromal AD clinical trials and obser-

and can successfully complete tasks online. In addition, most of the

vational studies, and to identify suitable candidates for further in-clinic

sample self-identified as White and had high educational attainment.

assessment and treatment of cognitive impairment. This approach can

A crucial next step is to assess feasibility and validity of the online

ultimately have practical clinical applications in health care, epidemiol-

instruments in diverse populations. We are currently using culturally

ogy, and public health settings, to identify individuals at risk for AD and

tailored participant communications and digital advertising to increase

cognitive decline.

the enrollment of traditionally underrepresented populations (URPs)
in the study. These include recruitment strategies that adapt best prac-
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